IONIS PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03186989
- Locations
- 🇸🇪
Karolinska University Hospital Huddinge, Stockholm, Sweden
🇫🇮Clinical Research Services Turku CRST, Turku, Finland
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03165864
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT03101878
- Locations
- 🇨🇦
Syneos Health, Toronto, Ontario, Canada
A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02910635
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT02900027
- Locations
- 🇨🇦
BioPharma Services, Toronto, Ontario, Canada
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02824003
- Locations
- 🇦🇹
Ionis Investigator Site, Vienna, Austria
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02709850
- Locations
- 🇨🇦
Clinical Site, Toronto, Ontario, Canada
Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT02583919
- Locations
- 🇺🇸
Ionis Investigational Site, Olympia, Washington, United States
🇺🇸Isis Investigational Site, Spring Valley, California, United States
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT02553889
- Locations
- 🇨🇦
Ionis Investigative Site, Montreal, Quebec, Canada
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02519036
- Locations
- 🇬🇧
University College London, London, United Kingdom
🇩🇪Ulm University Hospital, Ulm, Germany
🇬🇧Cambridge University Hospital, Cambridge, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath